Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MZE829 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MZE829 | EXPERIMENTAL | Cohort 1: Chronic kidney disease with concurrent diabetes Cohort 2: Chronic kidney disease without concurrent diabetes |
| Name | Type | Description |
|---|---|---|
| MZE829 | DRUG | Capsules for oral administration |
Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cer...
MZE829 is an investigational small molecule being developed for the treatment of proteinuric kidney disease, specifically in adults with APOL1 kidney disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
MZE829 targets APOL1, a gene associated with kidney disease. By targeting APOL1, the drug aims to address the underlying genetic cause of proteinuric kidney disease in affected individuals.
MZE829 is being developed by Maze Therapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of MZE829 in patients with proteinuric kidney disease.
MZE829 is currently in Phase 2 clinical development. It is being studied in a Phase 2 trial that is actively recruiting participants, indicating that the drug is still in the investigational stage and not yet approved for commercial use.
MZE829 is being evaluated in a Phase 2 clinical trial with the identifier NCT06830629. This study is recruiting adults with APOL1 kidney disease and proteinuric kidney disease, with an enrollment target of 74 participants across the United States, France, and the United Kingdom.
No, MZE829 is not the same as APOL1. APOL1 is the gene targeted by MZE829. MZE829 is a small molecule drug designed to act on APOL1 to treat proteinuric kidney disease, whereas APOL1 is the biological target itself.